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Introduction
Kratom is an herbal supplement (leaves of extracts(s) of the Mitragyna speciosa tree in the coffee family) that originated in South-East Asia where it is chewed or ingested as a tea to either give energy or curb anxiety. In small doses, Kratom works as a stimulant, but in higher-doses it has sedative and anti-nociceptive effects (1) . Often times, supplements are taken to fortify or maintain health and are believed to be innocuous (2) . There is evidence that most supplements do not prevent disease or death, and their use is not justified when they have no clear benefit because they could be harmful (3) . Since the 1990s, Kratom has become a popular recreational drug in the West. This is largely due to migration of people from Asia to theU.S. and from the dissemination of information through internet marketing (4) . Its true prevalence of usage has remained unclear due to limited reports. In 2016, several million consumers were reported purchasing Kratom from greater than 10,000 retail locations in the U.S. with an estimated annual market of 207 million U.S. dollars (5) . Anecdotal reports have included side effects such as seizure, hypothyroidism, hepatotoxicity, and coma (1, (6) (7) (8) . In a case report, Kratom has shown to produce reversible injury to the posterior white matter of the brain (9) . We report a patient with chronic monotherapy Kratom use who developed focal epilepsy.
Case Report
A 19-year-old right-handed Caucasian male with anxiety was without risks factors for epilepsy.
He was evaluated after experiencing a first seizure. He was initially found down at school, in the bathroom with post-event confusion and was suspected to have experienced an unwitnessed generalized tonic-clonic (GTC) seizure. He was concurrently being treated with intermittent lisdexamfetamine dimesylate usage for attention deficit hyperactivity disorder. A brain MRI
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performed shortly after the first seizure was reported to reveal no focal abnormalities. A complete metabolic profile, blood count, urine drug screen, and electroencephalogram were within normal limits. He was not treated with anti-seizure drugs (ASDs).
One year later, the patent experienced a second seizure characterized by awakening from sleep in a transient "dream-like reverie state," with generalized muscle soreness and tongue laceration. At this time, the patient admitted to excessive use of Kratom (several pills per day) for several months to self-treat anxiety. Typically, Kratom dosage can vary between 2 to 8 grams, producing stimulant to sedative effects, respectively. Further, ASDs were not administered for a suspected provoked seizure.
After the third unwitnessed focal seizure, he was prescribed levetiracetam (LEV), 500 mg tablet twice daily. Despite treatment, a witnessed focal to bilateral GTC seizure occurred 21 months after the first event, despite of taking LEV. The event was initially described as "blacking out" with disorientation and lip smacking prior to the GTC seizure. At this time, the patient admitted to continued use of Kratom. A urine drug screen returned negative. Lisdexamfetamine dimesylate and alprazolam had been discontinued, but he continued taking Kratom as an affordable and available means of alleviating anxiety and providing him with energy. After his fifth GTC seizure, he admitted to being non-compliant with LEV due to changes in mood and was switched to lamotrigine for its mood elevating effects.
The sixth GTC seizure resulted in a motor vehicle accident. In addition to Kratom use, he then admitted to intermittent use of marijuana (once weekly), lisdexamfetamine dimesylate use (3
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times weekly), rare alprazolam use (monthly), and intermittent alcohol consumption (4 drinks weekly). He followed up with Psychiatry and due to chronic Kratom abuse was recommended to drug rehabilitation.
After switching to lamotrigine and discontinuing Kratom the patient was seizure-free.
Nonetheless, breakthrough seizures were noted when a relapse of Kratom abuse occurred. A brain MRI performed 29 months after the initial seizure revealed bilateral symmetric T1 hyperintensity in the diencephalon including the globus pallidus, subthalamic nuclei, and portions of the cerebral peduncles (FIGURE 1). Repeat metabolic profiles were within normal limits. After successful completion of a substance abuse rehabilitation program, no further seizures were reported. A follow-up brain MRI was sought to visualize if structural brain abnormalities had subsided since discontinuation of Kratom, but the patient was lost to follow-up when insurance changed.
Discussion
Herbal supplements are used for their perceived benefits without much consideration given to harmful properties. They are used globally and the prevalence of usage continues to rise. Like patients abusing illicit drugs, our patient abusing Kratom benefited from detoxification at a supervised facility with trained medical professionals to monitor and provide medical support during the process. Kratom use in the U.S. has received limited attention yet the active ingredients are alkaloid substances called mitragynine and 7-hydroxymitragynine, and are mediated via the monoaminergic and opioid (mu-and kappa-) receptors (10) . These mechanisms of action are similar to opioids partly due to its molecular structure referred to as biased agonist
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A N U S C R I P T (4) . Given the current worldwide opioid analgesic crisis and potential for misuse, abuse, and dependence, Kratom may be subject to recreational abuse.
There are a number of herbal supplements that cause seizures including Black cohosh (11), Bearberry (12), Ma Huang (13), kava-kava (12), Yohimbe (14) , and Monkshood (12) . On the other hand, herbal supplements have had putative anti-seizure effects, though the lack of evidence precludes this conclusion (15) . For example, exogenous cannabinoids can mimic the Currently, no standard methods exist to detect Kratom or its metabolites on drug screening after ingestion and this is a contributing factor to its abuse potential. Like our patient, this also
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complicates the clinical scenario for the treating physician and delays management (10) .
Evidence also suggests high rates of dependency, development of withdrawal symptoms, and craving among chronic users (19) . In one study, more than half of regular Kratom users (>6 months) developed severe withdrawal symptoms while 45% demonstrated moderate dependency (19) . Consequently, withdrawal symptoms tend to worsen with chronic use. In a retrospective review in Thailand, 52 Kratom cases were identified of which 76.9% resulted in Kratom congress, and arguments made by the American Kratom Association resulted in the DEA to withdraw its proposition (4) . Consequently, the DEA, with input from the Food and Drug Administration (FDA) and National Institute on Drug Abuse undertook a full abuse potential assessment of Kratom use to develop regulatory recommendations (5) . The conclusion was Kratom did not appear to be of a public health threat and emergency scheduling of this supplement or any of its specific alkaloids was considered insignificant (4). Additionally, it was
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suggested that those individuals who consume Kratom for reasons other than recreational use may resort to illicit unregulated Kratom venders, thus exposing them to additional risk (4) . Since the banning of its importation by the FDA, its availability has flown under the radar and has increased. It is now being sold in powder and tablet form at tobacco stores, and marketed in shops, purchased online, or mixed into drinks.
Conclusion
We associate structural brain abnormality on MRI and symptomatic focal epilepsy with chronic 
